Results 251 to 260 of about 61,557 (297)
Some of the next articles are maybe not open access.
Pediatric Transplantation, 2004
Abstract: Advances in maintenance immunosuppression over the past decade has resulted in dramatic improvements in short‐ and long‐term outcomes in organ transplantation as well as a decreased incidence of acute rejection. However, immunosuppressive drugs need to be given long term, lack specificity, and are accompanied by adverse metabolic ...
Nancy R, Krieger, Sukru, Emre
openaire +2 more sources
Abstract: Advances in maintenance immunosuppression over the past decade has resulted in dramatic improvements in short‐ and long‐term outcomes in organ transplantation as well as a decreased incidence of acute rejection. However, immunosuppressive drugs need to be given long term, lack specificity, and are accompanied by adverse metabolic ...
Nancy R, Krieger, Sukru, Emre
openaire +2 more sources
[Pharmacogenetics of immunosuppressants].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2015Individualized drug therapy with immunosuppressants is an hot topic in transplantation. Therapeutic drug monitoring (TDM) is currently utilized to guide therapy, but toxic or subtherapeutic concentrations can only be identified after the drug is administered.
Cojutti P. G., Baraldo M.
openaire +3 more sources
Pharmacologic immunosuppression
Frontiers in Bioscience, 2004Clinical organ transplantation only became a viable treatment option after the advent of effective pharmacologic immunosuppression. Azathioprine and steroids were among the first drugs available for pharmacologic immunosuppression allowed for the first long-term successes in kidney and liver transplantation, though survivors experienced significant ...
Neal R, Barshes +2 more
openaire +2 more sources
Immunosuppression by Discodermolide
Annals of the New York Academy of Sciences, 1993In summary, discodermolide, a novel, marine-derived compound, is a potent in vitro and in vivo immunosuppressive agent. Discodermolide blocks cellular proliferation in lymphoid and nonlymphoid cells. This blocking action is not due to cytotoxicity. Blockage of cell proliferation by discodermolide appears to occur at the G2/M interface of the cell cycle,
Longley, R. E. +4 more
openaire +3 more sources
Transplantation, 2006
Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general,
openaire +2 more sources
Induction immunosuppression is intense, prophylactic therapy used at the time of transplantation based on the empiric observation that more powerful immunosuppression is required to prevent acute rejection early. In the past decade, there has been a growing trend towards the use of specialized agents such as antibody therapies for induction. In general,
openaire +2 more sources
Current Opinion in Immunology, 1992
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Surgical Clinics of North America, 1999
Although several new immunosuppressive medications have been developed in the past decade, many possible avenues are yet to be explored. Although the newer agents have not reflected any clear benefit in patient or graft survival over CsA or tacrolimus, they have been useful in reducing the incidence and severity of rejection, reducing the concomitant ...
A, Jain +4 more
openaire +2 more sources
Although several new immunosuppressive medications have been developed in the past decade, many possible avenues are yet to be explored. Although the newer agents have not reflected any clear benefit in patient or graft survival over CsA or tacrolimus, they have been useful in reducing the incidence and severity of rejection, reducing the concomitant ...
A, Jain +4 more
openaire +2 more sources
Current Pharmaceutical Design, 2008
The often fatal sepsis syndrome is characterized by the systemic release of inflammatory mediators, which is regulated and counterbalanced by the coordinated expression of anti-inflammatory molecules. The magnitude of sepsis-induced tissue injury and subsequent risk of infectious complications is dictated by the balance between the expression of pro ...
Kenneth, Lyn-Kew, Theodore J, Standiford
openaire +2 more sources
The often fatal sepsis syndrome is characterized by the systemic release of inflammatory mediators, which is regulated and counterbalanced by the coordinated expression of anti-inflammatory molecules. The magnitude of sepsis-induced tissue injury and subsequent risk of infectious complications is dictated by the balance between the expression of pro ...
Kenneth, Lyn-Kew, Theodore J, Standiford
openaire +2 more sources
Immunosuppressive Cyclolignans
Journal of Medicinal Chemistry, 1996The immunosuppressive activity of several lactonic, nonlactonic, and heterocycle-fused cyclolignans has been demonstrated for the first time by use of a T-cell-mediated immune response. Of the compounds tested, 4'-demethyldeoxypodophyllotoxin (8), beta-apopicropodophyllin (6), and the isoxazoline-fused cyclolignan 15 are the most potent with respect to
M, Gordaliza +5 more
openaire +2 more sources
Frontiers in Immunosuppression
Transplantation Proceedings, 2008Immunosuppressive therapy has relied on tailoring combinations of relatively nonselective drugs to individual patient tolerance. The next steps in the development of small molecule agents are to define and to develop selective inhibitors of cascades unique to T cells.
openaire +3 more sources